General Information of Drug (ID: DMG2LVM)

Drug Name
WR-289012 Drug Info
Synonyms WR-289012; CHEMBL385631; 3-(naphthalen-2-yl)-1-(2,3,4-trimethoxyphenyl)prop-2-en-1-one
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
44419435
CAS Number
CAS 914383-91-8
TTD Drug ID
DMG2LVM

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
KENPAULLONE DMAGVXW Discovery agent N.A. Patented [2]
APIGENIN DMI3491 Discovery agent N.A. Investigative [2]
2,5-dichloro-N-p-tolylthiophene-3-sulfonamide DMU5J8Y Discovery agent N.A. Investigative [3]
WR-289010 DMS2QUL Discovery agent N.A. Investigative [1]
WR-080539 DMUCGK8 Discovery agent N.A. Investigative [1]
5-chloro-4-nitrothiophene-2-sulfonamide DMRS82Q Discovery agent N.A. Investigative [3]
Oxindole derivative DM1AU8V Malaria 1F40-1F45 Investigative [4]
WR-203581 DM9M1UO Discovery agent N.A. Investigative [1]
WR-289009 DM5W9GR Discovery agent N.A. Investigative [1]
N-(2-aminoethyl)isoquinoline-5-sulfonamide DMG2MSX Discovery agent N.A. Investigative [5]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Plasmodium CDK Pfmrk (Malaria Pfmrk) TTSFWA7 P90584_PLAFA Inhibitor [1]

References

1 Selective inhibition of Pfmrk, a Plasmodium falciparum CDK, by antimalarial 1,3-diaryl-2-propenones. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1982-5.
2 A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different class... J Med Chem. 2004 Oct 21;47(22):5418-26.
3 Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases, Bioorg. Med. Chem. Lett. 20(13):3863-3867 (2010).
4 Novel molecular targets for antimalarial chemotherapy. Int J Antimicrob Agents. 2007 Jul;30(1):4-10.
5 Evaluation of broad spectrum protein kinase inhibitors to probe the architecture of the malarial cyclin dependent protein kinase Pfmrk. Bioorg Med Chem Lett. 2007 Sep 1;17(17):4961-6.